Bainan Biotech secures DKK 6.7 million in a syndication loan from Vækstfonden

Bainan Biotech, a Copenhagen, Denmark-based biotech company, announced that it was granted a $1.1m COVID-19 Syndication Loan from the Vaekstfonden.

Together with previous investment from the BioInnovation Institute, this financing secure going concern of the company and support further development of our proprietary technology in juvenile osteoporosis. 

Bainan Biotech, founded in 2018 by CEO Tue Emborg as a spinout company based on research made at the University of Copenhagen, is a preclinical life science company commercializing novel dual acting GIP/GLP-2 peptide agonists addressing unmet needs in juvenile osteoporosis. The company has identified promising drug candidates, which boost the body’s bone-strengthening hormonal response to nutritional intake as a new way of treating osteoporosis. The therapeutic concept has been verified in exploratory clinical studies showing strong effects of native GIP and GLP-2 peptides on biomarkers of bone metabolism thus supporting human translation.